Opdivo Receives Breakthrough Therapy Designation for Advanced Bladder Cancer
June 30th 2016The FDA has granted Bristol-Myers Squibb's nivolumab (Opdivo) breakthrough therapy designation for the potential indication of unresectable locally advanced or metastatic urothelial carcinoma that has progressed on or after a platinum-containing regimen.
Read More